Dr. Robert A. Galemmo is a creative medicinal chemist, scientific and managerial leader. Throughout his career, Dr. Galemmo has led teams responsible for multiple clinical and development candidates in ‘Big Pharma’ and biotech. He initiated the medicinal chemistry effort for the new factor Xa anti-coagulant Apixaban/Eliquis, led the team that identified the clinical MET kinase inhibitor JNJ 38877605 for oncology and discovered the leukotriene antagonist RG 12525 for asthma. He has broad therapeutic area experience including CNS, Oncology, Cardiovascular, Inflammation and Gastrointestinal. Dr. Galemmo is named as an inventor on over 40 patents and applications; he is the author of more than 50 scientific publications. Dr. Galemmo specializes in strategic planning, project leadership, rational drug design, lead generation, multi-parameter optimization, compound design for enhanced CNS exposure and intellectual property development.